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ABSTRACT 
A simple, isocratic and stability indicating micellar liquid chromatographic (MLC) method containing a surfactant solution above its 
critical micellar concentration (CMC) was developed and validated for determination of Deferasirox (BTBA) content in active 
pharmaceutical ingredient and its pharmaceutical formulations. The analysis was performed in on isocratic mode at 400C 
temperature through Thermo Hypersil ODS 100mm×4.6mm, 3 µm particle size columns. The UV detection wavelength was set at 
250 nm in the mobile phase containing 0.1 M Cetyl trimethyl ammonium bromide (CTAB) buffer (pH – 2.5) and 10% 1-butanol. 
The method was successfully validated following as per the requirements of ICH guidelines. The proposed method was successfully 
applied as stability indicating method for determination of BTBA under different stressed conditions. The method allows accurate 
and reliable determination of BTBA for drug stability assay in pharmaceutical investigations. 
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INTRODUCTION: 
Deferasirox [4-[3,5-bis (2-hydroxyphenyl)-1H-1,2,4-
triazol-1-yl] benzoic acid (BTBA)] (Figure 1) is an oral 
iron chelator and well known antidote. BTBA is an 
orally active chelator that is selective for iron (as Fe3+). 
It is a tridentate, oral, iron-chelating agent used in the 
management of chronic iron overload secondary to 
various RBC transfusions, i.e., transfusional iron 
overload such as β-thalassemia sickle cell disease, other 
unusual anemias, and myeloproliferative disorders4. It is 
an initial oral medication prescribes for such patients in 
the USA. The affinity and selectivity of the molecule is 
very high towards iron with high affinity in a 2:1 ratio. 
BTBA can be efficiently processed as chronic iron 
toxicity such chelation therapy. BTBA is the first FDA 
approved oral drug for chronic iron overload
1
. 
A comprehensive survey of the literature for BTBA 
analysis reveals that only a few systematic methods are 
available in favor of BTBA, By Liquid Chromatography 
Mass Spectrophotometry (LC–MS)2. Terbium - 
sensitized fluorescence method, LC method for 
pharmaceutical formulation, a stability representative 
LC method for bulk drug and pharmaceutical dosage 
forms, comparative bioavailability, dispersion and 
dispersed in various drinks, Pharmacokinetics, 
allocation, metabolism, and emission and its iron 
complex, were reported. In this present study an attempt 
was made to develop a rapid and economical micellar 
liquid chromatographic method for assessment of BTBA 
in bulk and pharmaceutical formulation with improved 
sensitivity, precision and accuracy using Cetyl trimethyl 
ammonium bromide (CTAB) as surfactant above its 
critical micellar concentration. Micellar liquid 
chromatography is successfully used in the analysis of 
variety of compounds in several types of samples
3-4
. 
MATERIAL AND METHODS: 
Chemicals and reagents 
BTBA standard was obtained as a gift samples from 
Medilux Laboratories Pvt. Ltd and it’s formulate table 
“Desirox-250 mg” (Cipla pharmaceutical Ltd) were 
procure from a viable source.  All Reagents were of 
analytical grade and solvents were of HPLC grade.  
Instrumentation 
An analytical balance, pH, vortex shaker were used to 
prepare the standard and sample solution. 
Chromatographic separations were performed in an 
Agilent and Waters Separation HPLC. The photo 
stability chamber utilized during forced degradation 
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studies was controlled by a temperature controller. All 
measurements were carried out at 25±20C temperature. 
Micellar liquid chromatographic conditions 
Mobile phase was prepared by mixing of 0.1 M CTAB 
buffer solution at pH 2.50 and n-butanol in ratio of 
90:10 v/v and filtered through 0.22 mm nylon filter 
paper. The stationary phase was Thermo Hypersil ODS 
column 100mm X 4.6mm, 3µm. Mobile phase flow rate 
was 1.0 mL/minute and column temperature 400C 
temperature as well as detection wavelength of 250nm. 
The total run time was set as 15 minute and injection 
volume was 10 µl. Under these optimized analytical 
conditions, BTBA was eluted at about 3.6 minute as 
shown in Figure 2
5
. 
RESULTS AND DISCUSSION: 
Selection of appropriate detection wavelength 
Analysis of reference and test solutions were performed 
and peak purity spectra were obtained over a wavelength 
range 200-400 nm. It was found that 250 nm is the 
optimum detection wavelength to maximize the 
sensitivity of the BTBA. A typical UV-Vis absorption 
spectrum obtained with the present method is depicted 
in Figure 3.  
Surfactant concentration 
Various types of surfactants were used to optimize the 
surfactant selection. Each individual surfactant exhibited 
different type of selectivity for BTBA. The increased 
selectivity is achieved in CTAB surfactant media. The 
effect of Cetyl trimethyl ammonium bromide (CTAB) 
buffer concentration on asymmetry, retention time and 
efficiency of BTBA was studied. After optimization of 
these variables, best shape and lowest peak tailing were 
achieved with well-defined peaks and good sensitivity 
within a reasonable analytical run time. 
Effect of the pH variation 
To study the effect of pH on Peak response, Retention 
time, Peak tailing, Peak area, Peak height and 
Theoretical number of plate, Injections (each time) were 
made using 0.1 M CTAB buffered solution between pH 
4.8 to pH 2.0. It was observed that 0.1 M CTAB buffer 
pH 2.50 gave good combination between peak 
symmetry and analysis time.  
Method Validation  
The validation of the proposed method was performed 
according to ICH guidelines17 pertaining to the 
Specificity (Identification and force degradation), 
system suitability solution, linearity, range, LOD, LOQ, 
accuracy (recovery), precision, sample solution stability 
and robustness18. All the measurements for validation 
were performed using BTBA standard solution in 
mobile phase. 
Specificity  
Specificity of proposed method was determined by 
injecting sample and standard solutions. It was checked 
that no interference was created by blank and placebo at 
the retention time of BTBA peak. Peak purity of 
stressed samples was checked and confirmed the 
spectral purity of BTBA.  The obtained results indicated 
that the proposed method is selective and able to 
determine BTBA and its degradation impurities.  
Instrumental precision 
The instrumental precision was checked by injecting six 
replicates of standard solution containing BTBA (0.1 
mg mL-1 ) and % RSD, Peak asymmetry and Number of 
theoretical plate counts were determined. %RSD was 
found 0.37%, Peak asymmetry-1.34 and Theoretical 
plate – 1916, respectively. 
Linearity and range 
Linearity of assay test method was carried out 
progressively diluting BTBA standard stock solution. A 
calibration curve was obtained by plotting area response 
against concentration in ppm and calculate residual sum 
of the squares (r2), slope and y-intercept using the plot.  
Accuracy 
The accuracy of the method was ascertained by 
calculating recoveries of BTBA by the standard addition 
method. Known amount of standard of BTBA was 
spiked in three different levels (80%, 100% and 120%) 
and prepared three spiked samples at each level (Total 9, 
determinations are as per ICH guideline). These spiked 
samples were analyzed against working standard and 
recovery of BTBA in three different levels was 
calculated. The obtained recovery found in ranged 
between 99.28% - 99.63%.   
Precision study (repeatability and reproducibility) 
the method precision of the proposed method was 
determined by preparing six different sample solutions 
of same batch and analyzed against working standard 
solutions. Assay values of these all six samples were 
calculated. % RSD of assay values were found 0.21%.  
The low % RSD values indicate that the proposed 
method is precise and repeatable. Intermediate precision 
study was performed by same concentrations as 
prepared in method precision and analyzed against 
working standard solutions on different days. % RSD of 
assay values of 12 samples (Method and Instrument 
precision sample) were found to be 0.30%. The 
closeness of assay results and % RSD values indicate 
that the proposed method is reproducible. 
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Figure 1:  Structure of 
Deferasirox (BTBA)  
Figure 2 : Typical chromatogram of 
BTBA after Optimized 
chromatographic condition 
Figure 3 : Absorption spectrum of 
BTBA 
CONCLUSIONS: 
Micellar liquid chromatography described the 
optimization strategy used to select the best mobile 
phase for the resolution and determination of compounds 
in pharmaceutical preparations, serum, urine, and food 
samples. The projected method was found accurate, 
simple, precise, rapid and economical. Method 
validation parameters meet the specifications laid down 
in ICH guidelines with satisfactory results in the 
linearity, selectivity, precision, accuracy (recovery) and 
robustness. It is worth to mention that proposed 
methodology meets the fundamentals of the “green 
chemistry” exploring the use of environment-friendly 
reagents. Also the strategy is relatively inexpensive 
compared to other methods, thus making it more 
attractive and highly useful for many pharmaceutical 
analysis studies. 
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